Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A multicenter randomized double-blind placebo- and active-controlled Phase II study of single-dose QP002 Gel in unilateral total hip arthroplasty
CTR20240548Phase 2Completed
- Sponsor
- ClearPoint Biotech
- Start
- Mar 2024
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of QP002 in postoperative pain, sponsored by ClearPoint Biotech. Started Mar 2024; status: completed.
02
Drugs
QP002
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20240548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240548.